A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

PURPOSE. Angiogenesis is an important hallmark of breast cancer growth and progression. Pazopanib, an oral small molecule inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and KIT, has activity across a range of solid tumors. We evaluated the activity...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Taylor, Sara K., Chia, Stephen, Dent, Susan, Clemons, Mark, Agulnik, Mark, Grenci, Pamela, Wang, Lisa, Oza, Amit M., Ivy, Percy, Pritchard, Kathleen I., Leighl, Natasha B.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2010
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228026/
https://ncbi.nlm.nih.gov/pubmed/20682606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0081
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky